Bristol-Myers Squibb’s ORENCIA Receives FDA Approval for Treatment of Active Psoriatic Arthritis (PsA) in Adults

August 15, 2023
Posted by administrator

ORENCIA is now approved for the treatment of three autoimmune diseases:

Adult Rheumatoid Arthritis (RA)
Juvenile Idiopathic Arthritis (JIA)
Adult Psoriatic Arthritis (PsA) NEW
Psoriatic arthritis (PsA) is a chronic, inflammatory disease that can affect both the skin and musculoskeletal system.

Approximately 30% of individuals that are diagnosed with Psoriasis have PsA.

Symptoms of PsA include joint pain, stiffness and reduced range of motion. Most commonly affecting the distal joints (those closest to the nail) of the fingers or toes, as well as the wrists, knees, ankles and lower back. Joint symptoms typically include swelling, redness and warmth of a few or many joints, often in an asymmetric fashion. Individuals between the ages of 30 to 50 are usually affected, but can begin as early as childhood with men and women equally at risk.

Individuals diagnosed with PsA will now have another treatment option that their physician may subscribe.